{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide-statins","verification":{"valid":true,"entries":9,"head":"47911d0481591ba31783e80cc560ef599eaac7c3360fd26887039bd11d8a73b1"},"count":9,"sources":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","author":"","publisher":"","date":"","claim_ids":["c1"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:25.627Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5","source_role":"core_stack_evidence"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","author":"","publisher":"","date":"","claim_ids":["c2"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:45.532Z","link_status":"ok","quote_status":"verified","prev":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5","hash":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1","source_role":"core_stack_evidence"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","summary":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","author":"","publisher":"","date":"","claim_ids":["c3"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:45.532Z","link_status":"ok","quote_status":"verified","prev":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1","hash":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3","source_role":"core_stack_evidence"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","author":"","publisher":"","date":"","claim_ids":["c4"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"verified","prev":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3","hash":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb","source_role":"core_stack_evidence"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","summary":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","author":"","publisher":"","date":"","claim_ids":["c5"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"unverified","prev":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb","hash":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968","source_role":"core_stack_evidence"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","summary":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","author":"","publisher":"","date":"","claim_ids":["c6"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"unverified","prev":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968","hash":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4","source_role":"core_stack_evidence"},{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","author":"","publisher":"","date":"","claim_ids":["c7"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4","hash":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f","source_role":"core_stack_evidence"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","summary":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","author":"","publisher":"","date":"","claim_ids":["c8"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f","hash":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db","source_role":"core_stack_evidence"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","summary":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","author":"","publisher":"","date":"","claim_ids":["c9"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db","hash":"47911d0481591ba31783e80cc560ef599eaac7c3360fd26887039bd11d8a73b1","source_role":"core_stack_evidence"}]}